"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Mechanism of Action
The oral poliovirus vaccine stimulates the immune system to produce anti-poliovirus antibodies against Sabin poliovirus types 1, 2, and 3. The live virus persists in the gastrointestinal tract for 4-6 weeks, inducing both mucosal and serum anti-poliovirus antibodies capable of opsonization, neutralization, and complement activation. It is likely that reinfection with naturally occurring poliovirus or vaccine strains reinforces OPV-induced humoral immunity.
Antibody stimulation after oral administration of OPV occurs within 7-10 days and peaks at approximately 3 weeks. Poliovirus antibodies are distributed into breast milk. It is unknown if poliovirus antibodies cross the placenta (see CONTRAINDICATIONS). Most individuals are protected after one dose, and the majority of vaccinees are protected after two doses. The duration of immunity is not known, but studies in children have revealed that 95% of vaccinees have protective antibodies to all three virus types 5 years after vaccination.
Several studies suggest that intestinal resistance can persist for 6 years after vaccination.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Orimune Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.